Recode

ReCode Therapeutics Announces Appointment of Dean J. Mitchell as Chairman of Its Board of Directors

Retrieved on: 
星期一, 五月 13, 2024
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, LNP, Bristol Myers Squibb, Patient, Biology, City, University of London, GSK plc, ImmunoGen, Messenger, Recode, Therapy, Sale, MBA, Acquisition, King Pharmaceuticals, Coventry University

ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced the appointment of Dean J. Mitchell as chairman of its Board of Directors.

Key Points: 
  • ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced the appointment of Dean J. Mitchell as chairman of its Board of Directors.
  • Mr. Mitchell is a highly experienced and well-regarded biotechnology and pharmaceutical industry veteran who brings over three decades of experience as a board director and corporate executive to the ReCode board.
  • Mr. Mitchell previously served as board chairman of Kinnate Biopharma, Inc. until its sale in 2024 and as board director for ImmunoGen, Inc. until its sale in 2024.
  • He served as executive board chairman for Covis Pharma Holdings until its sale in 2020 and board chairman of PaxVax Corporation until its sale in 2018.

Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

Retrieved on: 
星期四, 五月 9, 2024
FDA, Bone marrow, CRISPR, Research, Recode, IND, KLKB1, Medicine, Polyneuropathy, NK, AATD, Corporation, Congress, Brain, TTR, Amyloidosis, Food, Gene editing, Conference, Eye, Corporate social responsibility, BLA, HAE, Therapy, Safety, Tissue, Cystic fibrosis, Cardiomyopathy, ATM, DNA, Intellia Therapeutics, Bank, EAACI, Lung, AAT, Social, ATTR, NTLA, Cell, Disease, Regeneron Pharmaceuticals, Patient, Liver, ESG, Pharmaceutical industry

“Intellia continues to make outstanding progress across our pipeline of in vivo and ex vivo single-dose CRISPR-based therapies.

Key Points: 
  • “Intellia continues to make outstanding progress across our pipeline of in vivo and ex vivo single-dose CRISPR-based therapies.
  • Additionally, Intellia plans to report topline results from the Phase 2 portion in mid-2024 and present full results at a medical meeting in the second half of 2024.
  • Collaboration Revenue: Collaboration revenue was $28.9 million during the first quarter of 2024, compared to $12.6 million during the first quarter of 2023.
  • Net Loss: Net loss was $107.4 million for the first quarter of 2024, compared to $103.1 million during the first quarter of 2023.

ReCode Therapeutics to Participate in May Conferences

Retrieved on: 
星期三, 五月 1, 2024
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Messenger, Recode, Therapy

ReCode Therapeutics , a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced that company management will participate in the upcoming May conferences:

Key Points: 

ReCode Therapeutics , a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced that company management will participate in the upcoming May conferences:

Renowned Alzheimer's Neurologist Dale Bredesen, MD, Joins Pacific Neuroscience Institute

Retrieved on: 
星期二, 四月 16, 2024
UCLA, Neurodegenerative disease, Alzheimer's disease, Duke University Hospital, Brain, University, Dementia, Recode, Hope, NIH, Risk, Arrest, University of California, PNI, Doctor of Philosophy, The New York Times, Research, Trial of the century, History, Confusion, Exercise, Documentation, Ageing, UCSF, Buck, Patient, Survivor, Neurology, Medicine, Faculty, Amnesia, Quality of life, Nobel, UC, Nursing

SANTA MONICA, Calif., April 16, 2024 /PRNewswire/ -- Pacific Neuroscience Institute® (PNI) is thrilled to announce that Dale Bredesen, MD, has joined Pacific Neuroscience Institute®. Over the past four months, as the senior director of the nascent Precision Brain Health program, he and his colleagues have been intensely focused on developing what promises to be the world's first formalized system to comprehensively address neurodegenerative disease in the world. While not quite ready for primetime, the excitement around the clinical implications for patients is palpable.

Key Points: 
  • SANTA MONICA, Calif., April 16, 2024 /PRNewswire/ -- Pacific Neuroscience Institute® (PNI) is thrilled to announce that Dale Bredesen, MD, has joined Pacific Neuroscience Institute®.
  • Taking a personalized, biological systemwide approach and becoming proactive about interventions, represent the first steps towards stopping Alzheimer's in its tracks."
  • Pacific Neuroscience Institute has a history of innovation that fits perfectly with the development of this novel program."
  • He directed the Program on Aging at the Burnham Institute and joined the Buck Institute as founding president and CEO.

Award-winning journalist and author Kara Swisher will explain how to navigate today's tech landscape at CompTIA ChannelCon 2024

Retrieved on: 
星期二, 四月 9, 2024
Information technology, BizTech, CompTIA, Education, Knowledge, CNN, Recode, Workforce, Cryptocurrency

DOWNERS GROVE, Ill., April 9, 2024 /PRNewswire/ -- Get ready to be electrified by a keynote session featuring award-winning tech journalist and best-selling author Kara Swisher at CompTIA ChannelCon 2024. Swisher is the host of On with Kara Swisher and co-host of the Pivot podcast with Scott Galloway. She is editor-at-large at New York Magazine, and co-founder of the technology website Recode, and tech conference Code, the country's premier conference on tech and media. Swisher is also a contributor for CNN.

Key Points: 
  • Keynote address will offer insight from Swisher's new book, "Burn Book: A Tech Love Story"
    DOWNERS GROVE, Ill., April 9, 2024 /PRNewswire/ -- Get ready to be electrified by a keynote session featuring award-winning tech journalist and best-selling author Kara Swisher at CompTIA ChannelCon 2024.
  • Swisher is the host of On with Kara Swisher and co-host of the Pivot podcast with Scott Galloway.
  • She is editor-at-large at New York Magazine, and co-founder of the technology website Recode, and tech conference Code, the country's premier conference on tech and media.
  • She will discuss the evolving tech landscape, the role of big tech companies, and the challenges and opportunities that lie ahead.

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress

Retrieved on: 
星期四, 二月 22, 2024
Research, Intellia Therapeutics, Regeneron Pharmaceuticals, Fatigue, Haemophilia, NK, CTA, Liver, Cystic fibrosis, ATM, A1AT, Amyloidosis, HAE, Therapy, European Medicines Agency, ATTR, Haemophilia B, DNA, European Commission, Hereditary angioedema, Recode, Conference, Cardiomyopathy, AATD, Civil service commission, Clinical trial, Facial muscles, CRISPR, Gene editing, Food, NTLA, KLKB1, Lung, NEJM, TTR, Patient, Medicine, Disease, Tissue, Pharmaceutical industry

Collaboration Revenue: Collaboration revenue decreased by $15.5 million to negative $1.9 million during the fourth quarter of 2023, compared to $13.6 million during the fourth quarter of 2022.

Key Points: 
  • Collaboration Revenue: Collaboration revenue decreased by $15.5 million to negative $1.9 million during the fourth quarter of 2023, compared to $13.6 million during the fourth quarter of 2022.
  • R&D Expenses: Research and development expenses increased by $9.0 million to $109.0 million during the fourth quarter of 2023, compared to $100.0 million during the fourth quarter of 2022.
  • G&A Expenses: General and administrative expenses increased by $5.4 million to $29.0 million during the fourth quarter of 2023, compared to $23.6 million during the fourth quarter of 2022.
  • Net Loss: The Company’s net loss was $132.2 million for the fourth quarter of 2023, compared to $113.4 million during the fourth quarter of 2022.

ReCode Therapeutics Announces First Participants Dosed in a Phase 1 Healthy Volunteer Clinical Study of Inhaled mRNA-Based Genetic Medicine, RCT2100, for the Treatment of Cystic Fibrosis

Retrieved on: 
星期三, 二月 21, 2024
Research, FDA, Genetics, Clinical Trials, Health, Pharmaceutical, General Health, Other Science, Science, Therapy, LNP, Investigational New Drug, Messenger, Recode, Cystic fibrosis, Food, Cell, Safety, Patient, Disease, IND, Trial of the century, Vaccine

“While progress has been made for many people with CF, those who do not benefit from existing modulators report feeling left behind and continue to face profound physical and emotional hardship from the disease.

Key Points: 
  • “While progress has been made for many people with CF, those who do not benefit from existing modulators report feeling left behind and continue to face profound physical and emotional hardship from the disease.
  • The Phase 1 double-blind, placebo-controlled, first-in-human study is designed to assess the safety and tolerability of a single ascending dose of inhaled RCT2100 administered via nebulizer.
  • The study is being conducted in New Zealand and ReCode anticipates enrolling approximately 32 healthy adults who will receive a single dose of either placebo or RCT2100.
  • ReCode plans to submit an Investigational New Drug application (IND) to the U.S. Food and Drug Administration for a Phase 1 trial of RCT2100 in CF patients in the first half of 2024.

ReCode Therapeutics to Participate in February Conferences

Retrieved on: 
星期二, 二月 20, 2024
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Clinical Trials, Therapy, Messenger, Recode

ReCode Therapeutics , a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced that company management will participate in the upcoming February conferences:

Key Points: 

ReCode Therapeutics , a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced that company management will participate in the upcoming February conferences:

Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis

Retrieved on: 
星期四, 二月 15, 2024
Therapy, LNP, Liver, MB, CRISPR, Gene editing, Messenger, Intellia Therapeutics, Recode, Cystic fibrosis, Mucus, NTLA, Lung, DSM-IV codes, Respiratory failure, Cell, CFTR, Patient, Medicine, Tissue, Research, DNA, Vaccine

and MENLO PARK, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, and ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced a strategic collaboration to develop novel genomic medicines for the treatment of cystic fibrosis (CF).

Key Points: 
  • and MENLO PARK, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, and ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced a strategic collaboration to develop novel genomic medicines for the treatment of cystic fibrosis (CF).
  • Intellia will be responsible for the design of the editing strategy and research-grade components for the investigational therapies.
  • “This collaboration provides further validation of ReCode's SORT LNP platform to deliver diverse gene editing modalities to specific cells and tissues.
  • By combining our highly synergistic technologies and capabilities, we are excited about the potential to enable a faster path for next-generation gene editing therapeutics to CF patients.”

Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis

Retrieved on: 
星期四, 二月 15, 2024
Health, Genetics, Other Science, Research, Science, Biotechnology, Therapy, LNP, Liver, MB, CRISPR, Gene editing, Intellia Therapeutics, Messenger, Recode, Cystic fibrosis, Mucus, NTLA, DSM-IV codes, Respiratory failure, Cell, CFTR, Patient, Medicine, Tissue, DNA, Vaccine

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, and ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced a strategic collaboration to develop novel genomic medicines for the treatment of cystic fibrosis (CF).

Key Points: 
  • Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, and ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced a strategic collaboration to develop novel genomic medicines for the treatment of cystic fibrosis (CF).
  • Intellia will be responsible for the design of the editing strategy and research-grade components for the investigational therapies.
  • “This collaboration provides further validation of ReCode's SORT LNP platform to deliver diverse gene editing modalities to specific cells and tissues.
  • By combining our highly synergistic technologies and capabilities, we are excited about the potential to enable a faster path for next-generation gene editing therapeutics to CF patients.”